Combined cancer treatment methods using selected antibodies...

Details Combined cancer treatment methods using selected antibodies... Combined cancer treatment methods using selected antibodies...

2003-08-15

2009-08-11

Goddard, Laura B (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S141100, C424S174100

Reexamination Certificate

active

07572448

ABSTRACT:
Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

REFERENCES:
patent: 4939098 (1990-07-01), Suzuki et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5213804 (1993-05-01), Martin et al.
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5834599 (1998-11-01), Chang et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 6194430 (2001-02-01), Camden et al.
patent: 6300308 (2001-10-01), Schroit
patent: 6312694 (2001-11-01), Thorpe et al.
patent: 6333348 (2001-12-01), Vogel et al.
patent: 6406693 (2002-06-01), Thorpe et al.
patent: 6783760 (2004-08-01), Thorpe et al.
patent: 6806354 (2004-10-01), Schroit
patent: 6818213 (2004-11-01), Thorpe et al.
patent: 7067109 (2006-06-01), Thorpe et al.
patent: 7247303 (2007-07-01), Thorpe et al.
patent: 7422738 (2008-09-01), Thorpe et al.
patent: 2002/0025319 (2002-02-01), Brams
patent: 2003/0004097 (2003-01-01), Schroit
patent: 2003/0228625 (2003-12-01), Toh et al.
patent: 2004/0131610 (2004-07-01), Thorpe et al.
patent: 2004/0131621 (2004-07-01), Thorpe et al.
patent: 2004/0131622 (2004-07-01), Thorpe et al.
patent: 2004/0161429 (2004-08-01), Thorpe et al.
patent: 2004/0170620 (2004-09-01), Thorpe et al.
patent: 2004/0175378 (2004-09-01), Thorpe et al.
patent: 2004/0208868 (2004-10-01), Thorpe et al.
patent: 2004/0213779 (2004-10-01), Thorpe et al.
patent: 2004/0219155 (2004-11-01), Thorpe et al.
patent: 2004/0265367 (2004-12-01), Thorpe et al.
patent: 2005/0002941 (2005-01-01), Thorpe et al.
patent: 2005/0129696 (2005-06-01), Thorpe et al.
patent: 2005/0136059 (2005-06-01), Thorpe et al.
patent: WO 00/02584 (2000-01-01), None
patent: WO 00/02587 (2000-01-01), None
patent: WO 01/03735 (2001-01-01), None
patent: WO 01/68709 (2001-09-01), None
Umeda et al (J of Immunology, 1989, 143:2273-2279).
Beck et al (Int J Cancer, 2006, 118:2639-2643).
Huang et al (Cancer Research, 2005, 65:4408-4416).
Ran et al (Int J Radiation Oncology Biol Phys, 2002, 54:1479-1484).
Maneta-Peyret et al (J of Immunological Methods, 1988, 108:123-127).
Rote et al, Clin Immunol Immunopathol, 1993, 66:193-200.
Janeway et al (Immunobiology, 2001, 5th Ed., Garland Publishing, New York).
Schneider-Gadicke et al (1995, Eur J Cancer, 31A:1326-30).
Ran et al (Clinical Cancer Research, 2005, 11:1551-1562).
Luster et al (J of Biological Chemistry, 2006).
Janeway et al (Immunobiology, 2001, 5th Ed., Garland Publishing, New York; IDS).
Hortobagyi (Cancer, 2000, 88:3073-3079).
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295, under the heading “Fv Structure and Diversity in Three Dimensions”.
Rudikoff et al (Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982, IDS).
Colman P. M. (Research in Immunology, 145:33-36, 1994).
Bendig M. M. (Methods: A Companion to Methods in Enzymology, 1995; 8:83-93).
MacCallum et al (J. Mol. Biol., 262, 732-745, 1996).
Casset et al (Biochemical and Biophysical Research Communications, 307:198-205, 2003).
Bevers et al (Clinical Immunology, 2004, 112:150-160).
Luster et al (J Biological Chemistry, 2006, 281:29863-71, IDS).
Ran et al (Clinical Cancer Research, 2005, 11:1551-1562, IDS).
Ahmad and Allen, “Antibody-Mediated Specific Binding and Cytotoxicity of Liposome-Entrapped Doxorubicin to Lung Cancer Cells in Vitro”,Cancer Res., 52:4817-4820, 1992.
Balasubramanian and Schroit, “Aminophospholipid Asymmetry: A Matter of Life and Death”,Annu. Rev. Physiol., 65:701-734, 2003.
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amnio Acid Substitutions”,Science, 147:1306-1310, 1990.
Curti, “Physical Barriers to Drug Delivery in Tumors”,Crit. Rev. Oncol./Hematol., 14:29-39, 1993.
Goren et al., “Targeting of Stealth Liposomes in erbB-2 (HER/2) Receptor: In Vitro and In Vivo Studies”,Brit. J. Cancer, 74:1749-1756, 1996.
Gura, “Systems for Identifying New Drugs Are Often Faulty”,Science, 278:1041-1042, 1997.
Güssow and Seemann, “Humanization of Monoclonal Antibodies”,Methods in Enzymology, 203:99-121, 1991.
Herbert et al., Eds., Dictionary of Immunology, 4th ed. London:Academic Press, 1995.
Ishida et al., A Combinatorial Approach to Producing Sterically Stabilized (Stealth) Immunoliposomal Drugs,FEBS Letters, 460:129-133, 1999.
Jain, “Barriers to Drug Delivery in Solid Tumors”,Scientific American., 271(1):58-65, 1994.
Lewis et al., “Differential Responses of Human Tumor Cell Lines to Anti-p185HER2 Monoclonal Antibodies”,Cancer Immunol. Immunother., 37:255-263, 1993.
Luster et al., “Plasma Protein Beta-2-glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells,”JBC Papers in Press, www.jbc.org/cgi/doi/10.1074/jbc., M605252200:1-20, 2006.
Maruyama et al., “Lipid Composition is Important for Highly Efficient Target Binding and Retention of Immunoliposomes”,Proc. Natl. Acad. Sci. USA, 87:5744-5748, 1990.
Mellman, “Where Next for Cancer Immunotherapy?”,The Scientist, 20(1):47-56, 2006.
Ran et al., “Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice”,Clin. Cancer Res., 11:1551-1562, 2005.
Ran et al., “Increased Exposure of Anionic Phospholipids on the Surface of the Tumor Blood Vessels”,Cancer Res.; 62:6132-6140, 2002.
Rudikoff, “Single Amino Acid Substitution Altering Antigen-Binding Specificity”,Proc. Natl. Acad. Sci. USA, 79:1979-1983, 1982.
Stancovski et al., “Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth”,Proc. Natl. Acad. Sci. USA, 88:8691-8695, 1991.
Strobel and Cannistra, “β1-Integrins Partly Mediate Binding of Ovarian Cancer Cells to Peritoneal Mesothelium in Vitro”,Gynecologic Oncology, 73:362-367, 1999.
Thorpe et al., “Tumor Infarction: Immunoconjugates that Coagulate the Vasculature of Solid Tumors”,Proceeding of the American Association for Cancer Research, 36:488, Abstract #2910, Mar. 1995.
Contractual European Search Report for counterpart PCT Application, PCT/US03/21925, mailed Mar. 31, 2004.
European Search Report for Counterpart European Application No. 03764600.7, dated Dec. 27, 2004.
International Search Report for counterpart PCT Application, PCT/US03/21925, mailed Feb. 24, 2005.
De Pascalis et al., “Grafting of ‘Abbreviated’ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody”,J. Immunol., 169:3076-3084, 2002.
Paul, “Fv Structure and Diversity in Three Dimensions”, InFundamental Immunology, Third Edition, 1993, pp. 292-295.

Affiliated with

Also associated with

Rating

Combined cancer treatment methods using selected antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combined cancer treatment methods using selected antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined cancer treatment methods using selected antibodies... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4134026